MXPA03002839A - Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7. - Google Patents

Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.

Info

Publication number
MXPA03002839A
MXPA03002839A MXPA03002839A MXPA03002839A MXPA03002839A MX PA03002839 A MXPA03002839 A MX PA03002839A MX PA03002839 A MXPA03002839 A MX PA03002839A MX PA03002839 A MXPA03002839 A MX PA03002839A MX PA03002839 A MXPA03002839 A MX PA03002839A
Authority
MX
Mexico
Prior art keywords
oxadiazoles
heterocycloalkyl
cycloalkenyl
cycloalkyl
optionally substituted
Prior art date
Application number
MXPA03002839A
Other languages
English (en)
Inventor
Edwige Lorthiois
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA03002839A publication Critical patent/MXPA03002839A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invencion proporciona 1,3,4 -tiadiazoles y 1,3,4 -oxadiazoles que tienen la siguiente formula (I): (Ver formula) en donde Y es S u O, R1 es alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, cicloalquenilo, arilo, heteroarilo o un grupo policiclico, optativamente sustituido, R2 es alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, cicloalquenilo o arilo optativamente sustituido, R3 es X2-R'3, en donde X2 es un grupo de union y R'3 es cicloalquilo, heterocicloalquilo, cicloalquenilo, arilo, heteroarilo, o un grupo policiclico, optativamente sustituido, o sus derivados farmaceuticamente aceptables, el proceso para su preparacion y sus uso para la fabricacion de un medicamento para el tratamiento de trastornos para los cuales el tratamiento con un inhibidor de PDE7 es relevante.
MXPA03002839A 2000-10-02 2001-10-01 Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7. MXPA03002839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors
PCT/EP2001/011330 WO2002028847A1 (en) 2000-10-02 2001-10-01 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
MXPA03002839A true MXPA03002839A (es) 2004-09-10

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002839A MXPA03002839A (es) 2000-10-02 2001-10-01 Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.

Country Status (43)

Country Link
US (1) US7122565B2 (es)
EP (2) EP1193261A1 (es)
JP (1) JP4177098B2 (es)
KR (1) KR100614158B1 (es)
CN (1) CN1639141A (es)
AP (1) AP1541A (es)
AR (1) AR035347A1 (es)
AT (1) ATE304003T1 (es)
AU (2) AU8994501A (es)
BG (1) BG107654A (es)
BR (1) BR0114391A (es)
CA (1) CA2424279A1 (es)
CZ (1) CZ2003857A3 (es)
DE (1) DE60113283T2 (es)
DK (1) DK1326853T3 (es)
DZ (1) DZ3440A1 (es)
EA (1) EA007179B1 (es)
EC (1) ECSP034534A (es)
EE (1) EE200300134A (es)
ES (1) ES2247166T3 (es)
GE (1) GEP20053459B (es)
GT (1) GT200100196A (es)
HN (1) HN2001000217A (es)
HR (1) HRP20030247A2 (es)
HU (1) HUP0301248A3 (es)
IL (1) IL155122A0 (es)
IS (1) IS6759A (es)
MA (1) MA25916A1 (es)
MX (1) MXPA03002839A (es)
NO (1) NO20031482D0 (es)
NZ (1) NZ524852A (es)
OA (1) OA12518A (es)
PA (1) PA8529501A1 (es)
PE (1) PE20020419A1 (es)
PL (1) PL366332A1 (es)
PT (1) PT1326853E (es)
SI (1) SI1326853T1 (es)
SK (1) SK3812003A3 (es)
SV (1) SV2003000633A (es)
TN (1) TNSN01139A1 (es)
WO (1) WO2002028847A1 (es)
YU (1) YU24503A (es)
ZA (1) ZA200302346B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1597385A1 (en) * 2002-11-13 2005-11-23 Bayer HealthCare AG DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
PT1775298E (pt) 2004-07-01 2013-06-12 Daiichi Sankyo Co Ltd Derivado de tienopirazol com atividade inibidora da pde 7
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
ES2533206T3 (es) * 2007-03-27 2015-04-08 Omeros Corporation Inhibidores de PDE7 para uso en el tratamiento de trastornos del movimiento
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
CN107375296A (zh) 2010-11-08 2017-11-24 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
WO2016198649A1 (en) * 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (es)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
DE69909592T4 (de) * 1998-02-17 2005-03-24 Roche Diagnostics Gmbh Verwendung von thiadiazolo[4,3-a]pyridine derivaten

Also Published As

Publication number Publication date
HUP0301248A2 (hu) 2003-10-28
EP1193261A1 (en) 2002-04-03
ZA200302346B (en) 2004-08-04
EA007179B1 (ru) 2006-08-25
EP1326853A1 (en) 2003-07-16
WO2002028847A1 (en) 2002-04-11
EP1326853B1 (en) 2005-09-07
YU24503A (sh) 2006-03-03
BG107654A (bg) 2003-12-31
KR100614158B1 (ko) 2006-08-21
JP4177098B2 (ja) 2008-11-05
SV2003000633A (es) 2003-04-03
AU8994501A (en) 2002-04-15
JP2004510769A (ja) 2004-04-08
MA25916A1 (fr) 2003-10-01
BR0114391A (pt) 2003-06-24
TNSN01139A1 (en) 2005-11-10
NZ524852A (en) 2004-09-24
KR20030068542A (ko) 2003-08-21
EE200300134A (et) 2003-08-15
DE60113283T2 (de) 2006-06-08
PE20020419A1 (es) 2002-07-18
SK3812003A3 (en) 2004-05-04
GEP20053459B (en) 2005-02-25
HUP0301248A3 (en) 2005-06-28
US7122565B2 (en) 2006-10-17
PT1326853E (pt) 2005-11-30
AR035347A1 (es) 2004-05-12
ECSP034534A (es) 2003-07-25
HRP20030247A2 (en) 2005-04-30
SI1326853T1 (sl) 2005-12-31
EA200300333A1 (ru) 2003-10-30
NO20031482L (no) 2003-04-01
OA12518A (en) 2006-05-29
DK1326853T3 (da) 2005-12-12
CN1639141A (zh) 2005-07-13
CA2424279A1 (en) 2002-04-11
NO20031482D0 (no) 2003-04-01
GT200100196A (es) 2002-07-18
HN2001000217A (es) 2002-06-13
AP2003002764A0 (en) 2003-03-31
DE60113283D1 (de) 2005-10-13
PL366332A1 (en) 2005-01-24
PA8529501A1 (es) 2003-06-30
AP1541A (en) 2006-01-11
ES2247166T3 (es) 2006-03-01
AU2001289945B2 (en) 2005-12-22
US20030045557A1 (en) 2003-03-06
DZ3440A1 (fr) 2002-04-11
IS6759A (is) 2003-03-27
ATE304003T1 (de) 2005-09-15
IL155122A0 (en) 2003-10-31
CZ2003857A3 (cs) 2004-02-18

Similar Documents

Publication Publication Date Title
TNSN01139A1 (en) New thiadiazoles and oxadiazoles and their use as phosphodiesterase -7 inhibitors
JO2646B1 (en) New differentiated cyclic compounds as beta - lactam inhibitors
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
IL162498A0 (en) (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
PL1678166T3 (pl) Inhibitory kinaz białkowych
BR0310057A (pt) melhoria do desenvolvimento de catarata e outras doenças oftálmicas
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
SE9701304D0 (sv) Compounds
EP1277744A4 (en) OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
MXPA05008923A (es) Compuestos de triazol utiles en terapia.
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson

Legal Events

Date Code Title Description
FG Grant or registration